Articles by Emily Menendez
Clarity announced the second phase of the SECuRE trial's third cohort has commenced, as has the phase 3 CLARIFY trial.
The NODESAFE model can aid in clinical decision-making and may spur consideration for adjuvant therapy in patients with RCC.
Enzalutamide plus leuprolide acetate and enzalutamide alone caused delayed MFS when compared with placebo plus leuprolide.
An in vitro model of EV-resistant bladder cancer showed that EV resistance was mainly due to resistance of the payload MMAE.
Single-port and multi-port RARP approaches were found to provide similar 1-year biochemical recurrence rates.
Similar to results from the intention-to-treat population, pembrolizumab was favored for its benefit of prolonging DFS.
At SUO 2023, Dr. Nicholas Corsi, UT Southwestern, presented one of the largest multinational studies on NAC in UTUC to date.
Almost half of all patients initiating 1L platinum-based chemotherapy were unable to receive maintenance avelumab treatment.
The nomogram outperformed 2 conventional models in predictive accuracy and showed higher benefit in decision curve analysis.
Pembrolizumab with CRT is a feasible treatment option for MIBC with promising CR rates and manageable toxicity.
Compared with ADT alone, apalutamide plus ADT had a favorable hazard ratio across all end points regardless of age.
There was a 57% increase in the number of non-European prostate cancer cases compared to previous association studies.
TKI monotherapy and TKI plus non-IO therapy was the most common subsequent treatment utilized after receiving IO-TKI.
Past 12 months, the effectiveness and safety between nivolumab plus ipilimumab and pembrolizumab plus axitinib were similar.
The TRAE rates of 1L nivolumab plus ipilimumab were low and remained consistent relative to clinical trials.
Researchers evaluated biomarkers to determine their prognostic potential for determining treatment modality for ccRCC.
Researchers sought to develop an NLP model to describe patients and tumor characteristics to more easily aggregate data.
A single priming dose of 177Lu-PSMA-617 followed by pembrolizumab maintenance was found to be a safe treatment for mCRPC.
PCSM was found to be lower after local therapy use in patients with higher-risk disease, particularly after RP.
The anti-PD-1 therapy met the trial’s key secondary endpoint of OS for patients with RCC following nephrectomy.
630 Madison Ave.
Manalapan, NJ 07726
© 2023 Mashup Media, LLC. All rights reserved.